Vigil Neuro
Dwayne Stanley, MBA, PMP, currently serves as the Senior Director of Program Management at Vigil Neuroscience, providing leadership in strategic and operational program management for lead development programs. Previous experience includes roles such as Director of Program Management at Kaleido Biosciences, where program alignment with corporate strategy was a primary focus, and Associate Director of Program Management at Epizyme, leading activities for TAZVERIK's approval. Dwayne has also held positions at Hologic, Hill-Rom, Nypro, Karl Storz Endovision, and Boston Scientific, contributing to a diverse range of program management and engineering initiatives. Dwayne holds an MBA in Project Management from Keller Graduate School of Management and a BS in Mechanical Engineering Technology from Wentworth Institute of Technology. Additionally, Dwayne has experience as an Adjunct Professor at Benjamin Franklin Institute of Technology.
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.